Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Head and Neck Cancer

  Free Subscription


Articles published in Br J Ophthalmol

Retrieve available abstracts of 6 articles:
HTML format



Single Articles


    April 2021
  1. LUO Y, Chen H, Ge S, Rao Y, et al
    Clinical and pathological risk factors for worse stage and mortality of eyelid and periocular squamous cell carcinoma.
    Br J Ophthalmol. 2021 Apr 20. pii: bjophthalmol-2020-317546.
    PubMed     Abstract available


    March 2021
  2. KLINGENSTEIN A, Samel C, Messmer EM, Garip-Kuebler A, et al
    Epidemiological characteristics and clinical course of eyelid squamous cell carcinoma patients from a large tertiary centre between 2009 and 2020.
    Br J Ophthalmol. 2021 Mar 12. pii: bjophthalmol-2020-317969.
    PubMed     Abstract available


    January 2021
  3. SINGH L, Singh MK, Rizvi MA, Pushker N, et al
    Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
    Br J Ophthalmol. 2021;105:48-56.
    PubMed     Abstract available


    October 2020
  4. VAN IPENBURG JA, Naus NC, Dubbink HJ, van Ginderdeuren R, et al
    Prognostic value of TERT promoter mutations in conjunctival melanomas in addition to clinicopathological features.
    Br J Ophthalmol. 2020 Oct 30. pii: bjophthalmol-2020-317405.
    PubMed     Abstract available


    July 2020
  5. HOLM F, Mikkelsen LH, Kamper P, Rasmussen PK, et al
    Ocular adnexal lymphoma in Denmark: a nationwide study of 387 cases from 1980 to 2017.
    Br J Ophthalmol. 2020 Jul 30. pii: bjophthalmol-2019-315637.
    PubMed     Abstract available


    April 2020
  6. KWON M, Lee JS, Lee C, Yoon DH, et al
    Prognostic factors for relapse and survival among patients with ocular adnexal lymphoma: validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification.
    Br J Ophthalmol. 2020 Apr 23. pii: bjophthalmol-2020-315875.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: